All updated as on -
By 2030, the market for breast cancer diagnostics is anticipated to reach USD 7.9 billion, growing at a CAGR of 8.9% from 2023 to 2030.
Breast cancer is a frequent medical condition that primarily affects female patients of proliferative illnesses. Particularly in the tissues of the breast, cancer develops. Breast cancer symptoms include changes in the breast's size and form, the presence of lumps, discharge from the nipples, scaly red spots in the breast, and skin irritation. Early cancer detection helps patients recover more quickly, further stops cancer cells from spreading to other body parts, and allows for the use of new therapies that are now on the market for treatment.
The pre-cancer, breast, and management of aberrant screening results elective healthcare sectors have been severely disrupted by the COVID 19 pandemic. This occurs as a result of the existing health disparities being exacerbated by the rising prevalence of breast cancer cases. In fact, major market players are making a variety of decisions to carry out R&D activities to develop new products and form strategic alliances to advance technology and test results pertaining to the market.
According to a data released by the World Health Organisation (WHO), 6.85,000 people will die from breast cancer worldwide in the year 2020, including around 2.3 million women. As a result, the global market for breast cancer diagnostics is expected to grow over the forecast period due to the rising prevalence of breast cancer patients. Furthermore, improvements and prospects in early illness diagnosis and screening are being brought about by technical developments in imaging. Tomosynthesis, another name for 3-D mammography, is one of the cutting-edge technologies. This test creates a 3D shape out of pictures of the breast taken at various angles.
Before a person experiences any symptoms of cancer, screening involves looking for signs of the disease. This will aid in the early detection of cancer. In truth, an abnormal tissue or cancer can be easily treated if it is found at an early stage. If symptoms started to emerge, the cancer may have already begun to spread. Breast magnetic resonance imaging, biopsy, and diagnostic mammography are a few of the screening methods used to find breast malignancies. Although these tests must be performed in order to diagnose breast cancer, there are hazards associated with them, including the possibility of false positive or negative results, radiation overexposure side effects, psychological stress, and the spread of dangerous cells.
Report Coverage
Global Breast Cancer Diagnostics research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Breast Cancer Diagnostics report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Breast Cancer Diagnostics competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Breast Cancer Diagnostics market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Breast Cancer Diagnostics market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Breast Cancer Diagnostics market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Genomic Health, NanoString Technologies Inc., Paragon Biosciences LLC, Siemens AG, Quest Diagnostics Incorporated, Koninklijke Philips N.V., Epigenomics Inc., AstraZeneca, Biocept Inc., Devicor Medical Products Inc.
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Breast Cancer Diagnostics market based on the below-mentioned segments:
Global Breast Cancer Diagnostics Market, By Type
Global Breast Cancer Diagnostics market, By Application
Global Breast Cancer Diagnostics Market, By End User
Global Breast Cancer Diagnostics market, Regional Analysis
Breast cancer is a frequent medical condition that primarily affects female patients of proliferative illnesses. Particularly in the tissues of the breast, cancer develops. Breast cancer symptoms include changes in the breast's size and form, the presence of lumps, discharge from the nipples, scaly red spots in the breast, and skin irritation. Early cancer detection helps patients recover more quickly, further stops cancer cells from spreading to other body parts, and allows for the use of new therapies that are now on the market for treatment.
The pre-cancer, breast, and management of aberrant screening results elective healthcare sectors have been severely disrupted by the COVID 19 pandemic. This occurs as a result of the existing health disparities being exacerbated by the rising prevalence of breast cancer cases. In fact, major market players are making a variety of decisions to carry out R&D activities to develop new products and form strategic alliances to advance technology and test results pertaining to the market.
According to a data released by the World Health Organisation (WHO), 6.85,000 people will die from breast cancer worldwide in the year 2020, including around 2.3 million women. As a result, the global market for breast cancer diagnostics is expected to grow over the forecast period due to the rising prevalence of breast cancer patients. Furthermore, improvements and prospects in early illness diagnosis and screening are being brought about by technical developments in imaging. Tomosynthesis, another name for 3-D mammography, is one of the cutting-edge technologies. This test creates a 3D shape out of pictures of the breast taken at various angles.
Before a person experiences any symptoms of cancer, screening involves looking for signs of the disease. This will aid in the early detection of cancer. In truth, an abnormal tissue or cancer can be easily treated if it is found at an early stage. If symptoms started to emerge, the cancer may have already begun to spread. Breast magnetic resonance imaging, biopsy, and diagnostic mammography are a few of the screening methods used to find breast malignancies. Although these tests must be performed in order to diagnose breast cancer, there are hazards associated with them, including the possibility of false positive or negative results, radiation overexposure side effects, psychological stress, and the spread of dangerous cells.
Report Coverage
Global Breast Cancer Diagnostics research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Breast Cancer Diagnostics report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Breast Cancer Diagnostics competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Breast Cancer Diagnostics market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2020 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2019 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Genomic Health, NanoString Technologies Inc., Paragon Biosciences LLC, Siemens AG, Quest Diagnostics Incorporated, Koninklijke Philips N.V., Epigenomics Inc., AstraZeneca, Biocept Inc., Devicor Medical Products Inc. |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Breast Cancer Diagnostics Market from 2021 to 2030.
- Market Forecast for Breast Cancer Diagnostics Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Breast Cancer Diagnostics competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Breast Cancer Diagnostics
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Breast Cancer Diagnostics market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Breast Cancer Diagnostics market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Genomic Health, NanoString Technologies Inc., Paragon Biosciences LLC, Siemens AG, Quest Diagnostics Incorporated, Koninklijke Philips N.V., Epigenomics Inc., AstraZeneca, Biocept Inc., Devicor Medical Products Inc.
Primary Target Market
- Market Players of Breast Cancer Diagnostics
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Breast Cancer Diagnostics market based on the below-mentioned segments:
Global Breast Cancer Diagnostics Market, By Type
- Imaging
- Biopsy
- Genomic Tests
- Blood Tests
- Others
Global Breast Cancer Diagnostics market, By Application
- Screening
- Diagnostic and Predictive
- Prognostic
- Others
Global Breast Cancer Diagnostics Market, By End User
- Hospitals & Clinics
- Diagnostic Centers & Medical Laboratories
- Others
Global Breast Cancer Diagnostics market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive breast cancer diagnostics market market research and competitor analysis for your business to help you develop more profound insights into the breast cancer diagnostics market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the breast cancer diagnostics market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.